VEWD
14.10.2021 14:50:07 CEST | Business Wire | Press release
Vewd , the leading provider of OTT software solutions, together with Vestel, Europe’s largest TV manufacturer, today introduced the Vewd Operator TV, a fully-featured Smart TV with a built-in, content-enriched Pay TV experience. Now, Pay TV Operators can win the retail Smart TV landscape.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211014005674/en/
Rather than up-selling Pay TV services through a separate set-top box or competing alongside other apps inside hard-to-discover Smart TV app environments, operators can now own the entire Smart TV consumer experience – from home screen to app discoverability – from the moment a consumer purchases the TV.
Operator TV combines Vewd’s industry-leading Smart TV software with Vestel’s TV manufacturing, warehousing and distribution expertise. Vestel produces TV’s for more than 100 of the world’s iconic brands, including JVC, Hitachi, Telefunken, and Toshiba. Operators not only benefit from having a leading manufacturer for their own or co-branded televisions, but also can rely upon Vestel’s robust logistics capabilities to ensure simplified procurement, warehousing and delivery of their Operator TV.
“Vestel is pleased to add our expertise in building high-quality, full-featured Smart TVs to empower Vewd’s Operator TV solution,” said Barış Altınkaya, Vestel Vice President of Marketing and Product Management. “By working directly with Vewd and the Operator, we can leverage our vast manufacturing and retail distribution experience to contribute in reducing time-to-market, enabling substantial Operator CapEx savings while delivering an experience that delights subscribers, reduces churn and improves subscriber satisfaction.”
Vewd’s Software-as-a-Service (SaaS) business model aligns Operator TV with Pay TV subscription models and revenue, distributing costs, development time and risk. Critical functionality comes standard in an Operator TV:
- Conditional Access available to ensure broadcast and IP content security
- Cloud-managed reference user experience (UX) or the Operator’s customized UI
- Content including premium OTT and video-on-demand, FAST channels and full support for broadcast channels
“Operators have tried different strategies to embrace Smart TV, but together with Vestel, we've made the first solution that seamlessly connects Pay TV and Smart TV,” said Aneesh Rajaram, CEO of Vewd. “Consumers are streaming more and connecting fewer devices to the TV. As a result, Operators are forced to fight for visibility among Smart TV apps. Vewd Operator TV ensures Operators of any size can seize control from the start and win the home’s most important screen.”
Vewd's Operator TV solution is enabled via Vewd’s white-labeled product suite which includes Vewd OS . Visit our website to learn more about the benefits of Operator TV .
About Vewd
Vewd is the leading provider of OTT and hybrid TV solutions, connecting consumers anywhere to the content they love. By making OTT possible on almost 40 million connected devices each year, Vewd leads the way in defining the future of entertainment. Our suite of products and services are crafted to simplify complexity and offer solutions that unite the entire value chain, from silicon vendors to end-users. Market leaders such as Sony, Hisense, TPV, Vodafone, Sagemcom, and many more rely on Vewd products and services. Follow us, as we make TV connected. Visit Vewd.com to learn more.
About Vestel
Comprised of 28 companies, Vestel Group is a multi-industry manufacturer that operates in consumer electronics, home appliances, professional displays, LED lighting, and EV Chargers. Testimony to the global importance of Zorlu Holding across multiple technology sectors, Vestel is not only thriving at home in Turkey, but also through a further 10 subsidiaries that have been set up in various other parts of the world. Thanks to its renowned manufacturing and R&D complex, Vestel exports to 157 countries and keeps its position as a global player. More information: vestelinternational.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211014005674/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom